A comprehensive peptidome profiling technology for the identification of early detection biomarkers for lung adenocarcinoma

PLoS ONE

Volumn 6, Issue 4, 2011, Pages

  Ueda, Koji ^a   Saichi, Naomi ^a   Takami, Sachiko ^b   Kang, Daechun ^a,c   Toyama, Atsuhiko ^a,c,d   Daigo, Yataro ^c   Ishikawa, Nobuhisa ^e   Kohno, Nobuoki ^e   Tamura, Kenji ^f   Shuin, Taro ^f   Nakayama, Masato ^g   Sato, Taka Aki ^d   Nakamura, Yusuke ^c   Nakagawa, Hidewaki ^a  

^a RIKEN   (Japan)

^b CSK Institute for Sustainability Ltd   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

^d SHIMADZU CORPORATION   (Japan)

^e HIROSHIMA UNIVERSITY   (Japan)

^f KOCHI MEDICAL SCHOOL   (Japan)

^g TOPPAN PRINTING CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMILORIDE SENSITIVE CATION CHANNEL 4; APOLIPOPROTEIN A4; APOLIPOPROTEIN A4 [268-284]; APOLIPOPROTEIN A4 [273-283]; APOLIPOPROTEIN E; APOLIPOPROTEIN E [194-214]; FIBRINOGEN; FIBRINOGEN ALPHA [4-15]; FIBRINOGEN ALPHA [5-15]; FIBRINOGEN ALPHA [5-16]; FIBRINOGEN ALPHA [6-15]; FIBRINOGEN ALPHA [7-15]; FIBRINOGEN ALPHA [7-16]; FIBRINOGEN ALPHA CHAIN DERIVATIVE; LIMBIN; LIMBIN [306-313]; PEPTIDE; TUMOR MARKER; UNCLASSIFIED DRUG; TUMOR PROTEIN;

ANALYTIC METHOD; ARTICLE; CANCER STAGING; CONTROLLED STUDY; EARLY DIAGNOSIS; EXPRESSIONIST PROTEOME SERVER PLATFORM; HIGH THROUGHPUT SCREENING; HUMAN; LIQUID CHROMATOGRAPHY; LUNG ADENOCARCINOMA; MULTIPLE REACTION MONITORING; PEPTIDOMICS; QUANTITATIVE ANALYSIS; RELIABILITY; SEQUENCE ANALYSIS; SERUM; SIGNAL TRANSDUCTION; TANDEM MASS SPECTROMETRY; ADENOCARCINOMA; CASE CONTROL STUDY; LUNG TUMOR; METABOLISM; RECEIVER OPERATING CHARACTERISTIC;

ADENOCARCINOMA; CASE-CONTROL STUDIES; CHROMATOGRAPHY, LIQUID; HUMANS; LUNG NEOPLASMS; NEOPLASM PROTEINS; ROC CURVE; TANDEM MASS SPECTROMETRY; TUMOR MARKERS, BIOLOGICAL;

EID: 79954551473     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0018567     Document Type: Article

References (36)

1. Parkin DM, (2001) Global cancer statistics in the year 2000. Lancet Oncol 2: 533-543.
2. Samet JM, Avila-Tang E, Boffetta P, Hannan LM, Olivo-Marston S, et al. (2009) Lung cancer in never smokers: clinical epidemiology and environmental risk factors. Clin Cancer Res 15: 5626-5645.
3. Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, et al. (2007) The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol 2: 706-714.
4. Henschke CI, Yankelevitz DF, Libby DM, Pasmantier MW, Smith JP, et al. (2006) Survival of patients with stage I lung cancer detected on CT screening. N Engl J Med 355: 1763-1771.
5. Gail MH, Muenz L, McIntire KR, Radovich B, Braunstein G, et al. (1988) Multiple markers for lung cancer diagnosis: validation of models for localized lung cancer. J Natl Cancer Inst 80: 97-101.
6. McCarthy NJ, Swain SM, (2001) Tumor markers: should we or shouldn't we? Cancer J 7: 175-177.
7. Brundage MD, Davies D, Mackillop WJ, (2002) Prognostic factors in non-small cell lung cancer: a decade of progress. Chest 122: 1037-1057.
8. Sung HJ, Cho JY, (2008) Biomarkers for the lung cancer diagnosis and their advances in proteomics. BMB Rep 41: 615-625.
9. Maurya P, Meleady P, Dowling P, Clynes M, (2007) Proteomic approaches for serum biomarker discovery in cancer. Anticancer Res 27: 1247-1255.
10. Gamez-Pozo A, Sanchez-Navarro I, Nistal M, Calvo E, Madero R, et al. (2009) MALDI profiling of human lung cancer subtypes. PLoS One 4: e7731.
11. Wollscheid B, Bausch-Fluck D, Henderson C, O'Brien R, Bibel M, et al. (2009) Mass-spectrometric identification and relative quantification of N-linked cell surface glycoproteins. Nat Biotechnol 27: 378-386.
12. Schiess R, Wollscheid B, Aebersold R, (2009) Targeted proteomic strategy for clinical biomarker discovery. Mol Oncol 3: 33-44.
13. Ueda K, Takami S, Saichi N, Daigo Y, Ishikawa N, et al. (2010) Development of serum glycoproteomic profiling technique; simultaneous identification of glycosylation sites and site-specific quantification of glycan structure changes. Mol Cell Proteomics 9: 1819-1828.
14. Ostroff RM, Bigbee WL, Franklin W, Gold L, Mehan M, et al. (2010) Unlocking biomarker discovery: large scale application of aptamer proteomic technology for early detection of lung cancer. PLoS One 5: e15003.
15. Villanueva J, Nazarian A, Lawlor K, Tempst P, (2009) Monitoring peptidase activities in complex proteomes by MALDI-TOF mass spectrometry. Nat Protoc 4: 1167-1183.
16. Shen Y, Tolic N, Liu T, Zhao R, Petritis BO, et al. (2010) Blood peptidome-degradome profile of breast cancer. PLoS One 5: e13133.
17. Lopez-Otin C, Bond JS, (2008) Proteases: multifunctional enzymes in life and disease. J Biol Chem 283: 30433-30437.
18. Overall CM, Blobel CP, (2007) In search of partners: linking extracellular proteases to substrates. Nat Rev Mol Cell Biol 8: 245-257.
19. Palermo C, Joyce JA, (2008) Cysteine cathepsin proteases as pharmacological targets in cancer. Trends Pharmacol Sci 29: 22-28.
20. Lopez-Otin C, Matrisian LM, (2007) Emerging roles of proteases in tumour suppression. Nat Rev Cancer 7: 800-808.
21. Egeblad M, Werb Z, (2002) New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2: 161-174.
22. Albrethsen J, Bogebo R, Gammeltoft S, Olsen J, Winther B, et al. (2005) Upregulated expression of human neutrophil peptides 1, 2 and 3 (HNP 1-3) in colon cancer serum and tumours: a biomarker study. BMC Cancer 5: 8.
23. Sasaki K, Takahashi N, Satoh M, Yamasaki M, Minamino N, (2010) A peptidomics strategy for discovering endogenous bioactive peptides. J Proteome Res 9: 5047-5052.
24. Anderson NL, Anderson NG, Pearson TW, Borchers CH, Paulovich AG, et al. (2009) A human proteome detection and quantitation project. Mol Cell Proteomics 8: 883-886.
25. Liu M, Li CF, Chen HS, Lin LQ, Zhang CP, et al. (2010) Differential expression of proteomics models of colorectal cancer, colorectal benign disease and healthy controls. Proteome Sci 8: 16.
26. Qiu FM, Yu JK, Chen YD, Jin QF, Sui MH, et al. (2009) Mining novel biomarkers for prognosis of gastric cancer with serum proteomics. J Exp Clin Cancer Res 28: 126.
27. Wang Q, Shen J, Li ZF, Jie JZ, Wang WY, et al. (2009) Limitations in SELDI-TOF MS whole serum proteomic profiling with IMAC surface to specifically detect colorectal cancer. BMC Cancer 9: 287.
28. Wong MY, Yu KO, Poon TC, Ang IL, Law MK, et al. (2010) A magnetic bead-based serum proteomic fingerprinting method for parallel analytical analysis and micropreparative purification. Electrophoresis 31: 1721-1730.
29. Huang Z, Shi Y, Cai B, Wang L, Wu Y, et al. (2009) MALDI-TOF MS combined with magnetic beads for detecting serum protein biomarkers and establishment of boosting decision tree model for diagnosis of systemic lupus erythematosus. Rheumatology (Oxford) 48: 626-631.
30. Ebert MP, Niemeyer D, Deininger SO, Wex T, Knippig C, et al. (2006) Identification and confirmation of increased fibrinopeptide a serum protein levels in gastric cancer sera by magnet bead assisted MALDI-TOF mass spectrometry. J Proteome Res 5: 2152-2158.
31. Gianazza E, Mainini V, Castoldi G, Chinello C, Zerbini G, et al. (2010) Different expression of fibrinopeptide A and related fragments in serum of type 1 diabetic patients with nephropathy. J Proteomics 73: 593-601.
32. Zito F, Drummond F, Bujac SR, Esnouf MP, Morrissey JH, et al. (2000) Epidemiological and genetic associations of activated factor XII concentration with factor VII activity, fibrinopeptide A concentration, and risk of coronary heart disease in men. Circulation 102: 2058-2062.
33. Dieplinger H, Ankerst DP, Burges A, Lenhard M, Lingenhel A, et al. (2009) Afamin and apolipoprotein A-IV: novel protein markers for ovarian cancer. Cancer Epidemiol Biomarkers Prev 18: 1127-1133.
34. Hanniman EA, Lambert G, Inoue Y, Gonzalez FJ, Sinal CJ, (2006) Apolipoprotein A-IV is regulated by nutritional and metabolic stress: involvement of glucocorticoids, HNF-4 alpha, and PGC-1 alpha. J Lipid Res 47: 2503-2514.
35. Galdzicka M, Patnala S, Hirshman MG, Cai JF, Nitowsky H, et al. (2002) A new gene, EVC2, is mutated in Ellis-van Creveld syndrome. Mol Genet Metab 77: 291-295.
36. Grunder S, Geissler HS, Bassler EL, Ruppersberg JP, (2000) A new member of acid-sensing ion channels from pituitary gland. Neuroreport 11: 1607-1611.